Stat1LoxP (Stat1 tm1Mam ) Mouse Model for Oncology and Immunology Studies


Selective inactivation of Stat1 in mammary cells indicates that its effect as a tumor suppressor in breast is direct.

STAT1 is considered a tumor suppressor, but it is not known if this effect occurs directly in mammary cells or secondarily by disrupting interferon signaling through the JAK/STAT1 pathway to induce immune responses. ERBB2/neu-induced breast cancer appeared sooner in mice lacking STAT1 only in mammary cells than in wild-type mice, indicating that STAT1 tumor suppression was intrinsic to mammary cells and not secondary to an induced immune response.

Potential Commercial Applications: Competitive Advantages:
Oncology
Immunology
 


Development Stage:
Pre-clinical

Inventors:

Lothar Hennighausen (NIDDK)  ➽ more inventions...


Intellectual Property:
Research Tool — Patent protection is not being pursued for this technology.

Publications:
Klover PJ, et al. PMID 21076615

Licensing Contact:
Admin. Licensing Specialist (ALS),
Email:
Phone:

OTT Reference No: E-111-2012-0
Updated: Mar 10, 2014